Company Filing History:
Years Active: 2016
Title: Innovations of Fernando Blanco in Androgen Receptor Research
Introduction
Fernando Blanco is an innovative inventor based in Valencia, Spain. He has made significant contributions to the field of androgen receptor research, particularly in the development of non-ligand binding pocket antagonists for the human androgen receptor. His work addresses critical therapeutic needs in the treatment of androgen-dependent conditions, including prostate cancer.
Latest Patents
Fernando Blanco holds a patent for "Androgen receptor ligands - Non ligand binding pocket antagonists for the human androgen receptor." This patent highlights a novel class of non-steroidal, small molecule AR antagonists that inhibit the transcriptional activity of the androgen receptor through non-ligand binding pocket-mediated modulation. The research demonstrates full antagonism in the androgen receptor with low micromolar potency and high selectivity over estrogen receptors and the glucocorticoid receptor.
Career Highlights
Blanco's career is marked by his dedication to advancing therapeutic strategies for prostate cancer. His innovative approach to targeting the androgen receptor offers a promising alternative to classical therapies that often lead to androgen resistance. His work is crucial in the ongoing search for effective treatments for various androgen-dependent conditions.
Collaborations
Fernando collaborates with notable colleagues, including David George Lloyd and Darren Fayne. Their combined expertise enhances the research and development of new therapeutic strategies in the field of androgen receptor modulation.
Conclusion
Fernando Blanco's contributions to androgen receptor research exemplify the importance of innovation in addressing complex medical challenges. His patent and collaborative efforts pave the way for new therapeutic options in the treatment of prostate cancer and other androgen-dependent conditions.